Substance P antagonists: The next breakthrough in treating depression?

Journal of Clinical Pharmacy and Therapeutics

Volumn 24, Issue 6, 1999, Pages 461-469

  Baby, S ^a   Nguyen, M ^a   Tran, D ^a   Raffa, Robert B ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; 5 [[2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 MORPHOLINYL]METHYL] N,N DIMETHYL 1H 1,2,3 TRIAZOLE 4 METHANAMINE; 5 AMINOVALERYLSUBSTANCE P [7-11][9 PROLINE 10 (N METHYLLEUCINE)]; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; APREPITANT; CITALOPRAM; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SUBSTANCE P; SUBSTANCE P ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ANIMAL EXPERIMENT; ANTICHOLINERGIC EFFECT; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; HUMAN; HYPERTENSION; META ANALYSIS; NONHUMAN; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS; DEPRESSION; DISEASE MODELS, ANIMAL; FORECASTING; HUMANS; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 0033370226     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1999.00257.x     Document Type: Review

References (61)

1. 1. American Psychiatric Association. (1994) Mood disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington, DC: American Psychiatric Association, 317-391.
2. 2. Wells BG, Mandos LA, et al. (1997) Depressive disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM eds. Pharmacology: a Pathophysiologic Approach. Stamford, CT: Appleton and Lange, 395-417.
3. 3. Bennett DA Jr, Phun L, Polk J, Voglino SA, Zlotnik V, Raffa RB. (1998) The neuropharmacology of St. John's wort (Hypericum). Annal of Pharmacotherapy, 32, 1201-1208.
4. 4. Kramer MS, Cutler N, Feighner J, et al. (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 281, 1640-1644.
5. 5. Winokur G. (1986) Unipolar depression. In: Winokur G, Clayton P eds. Medical Basis of Psychiatry. Philadelphia: W.B. Saunders, 60.
6. 6. Hirschfeld RMA, Cross CK. (1982) Epidemiology of affective disorders. Archives of General Psychiatry, 39, 35-46.
7. 7. Andreasen NC. (1984) The Broken Brain. The Biological Revolution in Psychiatry. New York. Harper & Row.
8. 8. Blazer D. (1989) Depression in the elderly. New England Journal of Medicine, 320, 164-166.
9. 9. Kornstein SC. (1997) Gender differences in depression: implications for treatment. Journal of Clinical Psychiatry, 58(Suppl. 15), 12-18.
10. 10. McGuffin P, Katz R. (1989) The genetics of depression and manic-depressive disorder. British Journal of Psychiatry, 155, 294-304.
11. 11. Bourne HR. (1998) Drug receptors & pharmacodynamics. In: Katzung BG, ed. Basic and Clinical Pharmacology. 7th edn. Stamford CT: Appleton and Lange, 9-33.
12. 12. Potter WZ, Hollister L. (1998) Antidepressant agents. In: eds. Basic and Clinical Pharmacology. 7th edn. Stamford CT: Appleto n and Lange, 483-495.
13. 13. Moller HJ, Volz HP. (1996) Drug treatment of depression in the 1990s. An overview of achievements and future possibilities. Drugs, 52, 625-638.
14. 14. Laird LK, Benefield WH. (1995) Mood disorders I: major depressive disorders. In: Young LY, Koda-Kimble MA eds. Applied Therapeutics: the Clinical Use of Drugs. 6th edn. Vancouver, WA: Applied Therapeutics, Inc., 76, 1-28.
15. 15. Constantine L. (1998) Newly approved SSRI enters U.S. market. Pharmacy Today, 4, 3.
16. 16. Stoudemire A. (1996) New antidepressant drugs and the treatment of depression in the medically ill patient. Psychiatric Clinics of North America, 19, 495-514.
17. 17. Raffa RB. (1998) Possible role(s) of neurokinins in CNS development and neurodegenerative or other disorders. Neuroscience and Biobehavioral Reviews, 6, 789-813.
18. 18. Fuxe K, Agnati LF, Ganten D, et al. (1981) The role of noradrenaline and adrenaline neuron systems and substance P in the control of central cardiovascular functions. In: Buckley JP, Ferrario CM, eds. Nervous System Mechanisms in Hypertension. New York: Raven Press, 89-113.
19. 19. von Euler US, Gaddum JH. (1932) An unidentified depressor substance in certain tissue extracts. Journal of Physiology (London), 72, 577-583.
20. 20. Mussap CJ, Geraghty DP, Burcher E. (1993) Tachykinin receptors: a radioligand binding perspective. Journal of Neurochemistry, 60, 1987-2009.
21. 21. Buck SH, (1994) The Tachykinin Receptors. Clifton NJ: Humana Press.
22. 22. Krause JE, Sachais BS, Blount P. (1994) Tachykinin receptors. In: Peroutka SJ, ed. Hand-Book of Receptors and Channels: G Protein-Coupled Receptors. Boca Raton, FL: CRC Press, 277-298.
23. 23. Helke CJ, Krause JE, Mantyh PW, Couture R, Bannon MJ. (1990) Diversity in mammalian tachykinin peptidergic neurons. multiple peptides, receptors, and regulatory mechanisms. FASEB Journal, 4, 1606-1615.
24. 24. Ogawa T, Kanazawa I, Kimura S. (1985) Regional distribution of substance P, neurokinin α and neurokinin β in rat spinal cord, nerve roots and dorsal root ganglia, and the effects of dorsal root section or spinal transection. Brain Research, 359, 152-157.
25. 25. Warden MK, Young WS III. (1988) Distribution of cells containing MRNAs encoding substance P and neurokinin B in the rat central nervous system. Journal of Comparative Neurology, 272, 90-113.
26. 26. Gerard NP, Garraway LA, Eddy RL Jr, et al. (1991) Human substance P receptor (NK-1): organization of the gene, chromosome localization, and functional expression of cDNA clones. Biochemistry, 30, 10640-10646.
27. 27. Hopkins B, Powell SJ, Dankal P, Briggs I, Graham A. (1991) Isolation and characterization of the human lung NK-1 receptor cDNA. Biochemical and Biophysical Research Communications, 180, 1110-1117.
28. 28. Takeda Y, Chou KB, Takeda J, Sachais BS, Krause JE. (1991) Molecular cloning, structural characterization and functional expression of the human substance P receptor. Biochemical and Biophysical Research Communications, 179, 1232-1240.
29. 29. Gerard NP, Eddy RL Jr, Shows TB, Gerard C. (1990) The human neurokinin A (substance K) receptor. Journal of Biological Chemistry, 265, 20455-20462.
30. 30. Kris RM, South V, Saltzman A, et al. (1991) Cloning and expression of the human substance K receptor and analysis of its role in mitogenesis. Cell Growth and Differentiation, 2, 15-22.
31. 31. Buell G, Schulz MF, Arkinstall SJ, et al. (1992) Molecular characterisation, expression and localisation of human neurokinin-3 receptor. FEBS Letters, 299, 90-95.
32. 32. Huang R-RC, Cheung AH, Mazina KE, Strader CD, Fong TM. (1992) cDNA sequence and heterologous expression of the human neurokinin-3 receptor. Biochemical and Biophysical Research Communications, 184, 966-972.
33. 33. Takahashi K, Tanaka A, Hara M, Nakanishi S. (1992) The primary structure and gene organization of human substance P and neuromedin K receptors. European Journal of Biochemistry, 204, 1025-1033.
34. 34. Poyner DR, Hanley MR. (1992) Molecular biology of peptide and glycoprotein hormone receptors. In: Brann MR, ed. Molecular Biology of G-Protein-Coupled Receptors. Boston: Birkhäuser, 198-232.
35. 35. Watling KJ. (1992) Nonpeptide antagonists herald new era in tachykinin research. Trends in Pharmacological Sciences, 13, 266-269.
36. 36. Lowe JA III, Drozda SE, Snider RM, et al. (1992) The discovery of (2S,3S) -cis-2-(diphenylmethyl) -N-[(2-methoxylphenyl)methyl]-1-azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonist. Journal of Medicinal Chemistry, 35, 2591-2600.
37. 1) receptor antagonist. Science, 251, 437-439.
38. 2) receptor. British Journal of Pharmacology, 105, 77P.
39. 2) receptor. Life Sciences, 50, PL101-PL106.
40. 3 receptor. Life Sciences, 56, PL27-PL32.
41. 41. Regoli D, Boudon A, Fauchére J-L. (1994) Receptors and antagonists for substance P and related peptides. Pharmacological Reviews, 46, 551-599.
42. 42. Richelson E. (1984) The newer antidepressants: structures, pharmacokinetics, pharmacodynamics, and proposed mechanisms of action. Psychopharmacology Bulletin, 20, 213-223.
43. 43. Nemeroff CB, Bissette G. (1985) Involvement of nonopioid peptides in the pathogenesis of neurological and psychiatric disorders: evidence from CSF and post-mortem studies. Progress in Clinical Biological Research, 192, 333-341.
44. 44. Barden N, Daigle M, Picard V, Di Paolo T. (1983) Perturbation of rat brain serotonergic systems results in an inverse relation between substance P and serotonin concentrations measured in discrete nuclei. Journal of Neurochemistry, 41, 834-840.
45. 45. Chan-Palay V, Jonsson G, Palay SL. (1978) Serotonin and substance P coexist in neurons of the rat's central nervous system. Proceedings of the National Acadamy of Sciences (USA), 75, 1582-1586.
46. 46. Hökfelt T, Ljungdahl A, Steinbusch H, et al. (1978) Immunohistochemical evidence of substance P-like immunoreactivity in some 5-hydroxytryptamine-containing neurons in the rat central nervous system. Neuroscience, 3, 517-538.
47. 47. Jones RSG, Olpe H-R. (1984) Monoaminergic modulation of the sensitivity of neurons in the cingulate cortex to iontophoretically applied substance P. Brain Research, 311, 297-305.
48. 48. Brodin E, Peterson L-L, Ögren S-O, Bartfai T. (1984) Chronic treatment with the serotonin uptake inhibitor zimelidine elevates substance P levels in rat spinal cord. Acta Physiologica Scandinavia, 122, 209-211.
49. 49. Brodin E, Ögren SO, Theodorsson-Norheim E. (1987) Effects of subchronic treatment with imipramine, zimelidine and alaproclate on regional tissue levels of substance P-and neurokinin A/neurokinin B-like immunoreactivity in the brain and spinal cord of the rat. Neuropharmacology, 26, 581-590.
50. 50. Brodin K, Rosén A, Iwarsson K, Ögren S-O, Brodin E. (1989) Increased levels of substance P and cholecystokinin in rat cerebral cortex following repeated electroconvulsive shock and subchronic treatment with a serotonin uptake inhibitor. Acta Physiologica Scandinavia, 136, 613-614.
51. 51. Rimón R, Le Grevés P, Nyberg F, Heikkilä L, Salmela L, Terenius L. (1984) Elevation of substance P-like peptides in the CSF of psychiatric patients. Biological Psychiatry, 19, 509-516.
52. 52. Berretini WH, Rubinow DR, Nurnberger JI Jr, Simmons-Alling S, Post RM, Gershon ES. (1985) CSF substance P immunoreactivity in affective disorders. Biological Psychiatry, 20, 965-970.
53. 53. Toresson G, Brodin E, Wahlström A, Bertilsson L. (1988) Detection of N-terminally extended substance P, but not of substance P in human cerebrospinal fluid-quantitation with HPLC-RIA. Journal of Neurochemistry, 50, 1701-1707.
54. 54. Mårtensson B, Nyberg S, Toresson G, Brodin E, Bertilsson L. (1989) Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatrica Scandinavia, 79, 586-596.
55. 55. Heikkilä L, Rimó R, Terenius L. (1990) Dynorphin A. and substance P in the cerebrospinal fluid of schizophrenic patients. Psychiatry Research, 34, 229-236.
56. 56. Rupniak NM, Williams AR. (1994) Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non penetrant tachykinin NK-1 receptor antagonists. European Journal of Pharmacology, 265, 179-183.
57. 57. Bristow LJ, Young L. (1994) Chromodacryorrhea and repetitive hind paw tapping: models of peripheral and central tachykinin NK1 receptor activation in gerbils. European Journal of Pharmacology, 253, 245-252.
58. 58. Shaikh MB, Steinberg A, Siegel A. (1993) Evidence that substance P is utilized in medial amyloid facilitation of defensive behavior in the cat. Brain Research, 625, 283-294.
59. 59. Hale JJ, Mills SG, MacCoss M, et al. (1998) Structural optimization affording 2-(R)-(1-(R)-3,5-bis(trifluoromethyl) phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. Journal of Medicinal Chemistry, 41, 4607-4614.
60. 60. Wahlestedt C. (1998) Reward for persistence in substance P research. Science, 281, 1624-1625.
61. 61. Enserink M. (1999) Can the placebo be the cure? Science, 284, 238-240.